WOCKPHARMANSE5 June 2025

Wockhardt Limited has informed the Exchange about Investor Presentation

Wockhardt Limited

Ref. No.: WOCK/SEC/SE/2025-26/014

5th June, 2025

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 Scrip Code: 532300

National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 NSE Symbol: WOCKPHARMA

Dear Sir/ Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended – Investor Presentation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and in continuation to our letter bearing reference no. Ref. No.: WOCK/SEC/SE/2025-26/012 dated 2nd June, 2025, please find enclosed herewith a copy of the updated Investor Presentation.

The said Investor Presentation will also be uploaded on the Company’s website and can be accessed through the following link:

https://www.wockhardt.com/investors/analyst-investors/presentation/

Kindly take the same on record please.

Thanking you,

For Wockhardt Limited

Rashmi Mamtura Company Secretary

Encls: as above

Investor Presentation June 2025

Disclaimer

This presentation contains “forward-looking statements” – that is, statements that relate to future, not past events or historical facts. All

forward-looking statements are based on judgments derived from the information available to the company at this time. Forward-looking

statements can be identified by terminology such as such as “potential,” “expected,” “will,” “planned,” or similar terms. Forward looking

statements are based on the current beliefs and expectations of Wockhardt regarding future events, and are subject to various risks and

uncertainties, many of which are difficult to predict. Actual results may differ materially from anticipated results. Such risks and

uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the

research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our

industry. We do not undertake any obligation to update any forward-looking statement in this presentation, whether as a result of changes

in underlying factors, new information, future events or otherwise. The information in this document have been collected with the purpose

to provide interested parties with information about Wockhardt. The information is not comprehensive or complete and thus does not

represent an adequate basis for a final decision about an investment.

Information contained in this document is to be used for the sole

purpose of evaluating potential strategic transactions or partnerships and cannot be used for any other purpose without specific written

and prior approval of Wockhardt. The presentation may not be copied, duplicated or transferred to third parties without the prior written

approval of Wockhardt.

Information contained in this document is to be used for the sole purpose of evaluating potential strategic transactions or partnerships and

cannot be used for any other purpose without specific written and prior approval

Global Research - driven multinational

INR 3,033 Cr.

FY25 Income

INR 418 Cr.

FY25 EBITDA

Novel Antibiotics

Biotechnology

Pharmaceuticals

Global Footprint

FY25 sales contribution (%)

12 manufacturing facilities across globe

2 R&D centers one each in India, UK

India

Emerging Markets

Ireland (& other EU)

39%

23%

12%

Stronger business performance

67% Y-o-Y EBITDA growth1

0.01 Net Debt : Equity ratio2

20% growth for biosimilars in emerging markets3

INR 326 Cr. Reduction in debt4

1. 2. 3. 4.

Growth in FY25 over FY24 As on 31st March 2025, excluding promoter debt & net of cash & cash equivalents and other bank balances (Net Debt: INR 64 Cr ; Equity: INR 4,657 Cr.) Growth in FY25 over FY24 As at 31st March 2025 vs 31st March 2024 (excluding promoter debt)

Key positives for FY24-25: Development milestones

ZAYNICH® (WCK 5222)

 Successful completion of global Phase III cUTI study with 20% superiority  Phase II Carbapenem-Resistant Organism study with >90% clinical efficacy  NDA filed with DCGI, India  Compassionate use: 51 lives saved

MIQNAF® (Nafithromycin)

 Approved & Launched in India  Grant of Breakthrough Medicinal Product (BMP) by Saudi Arabia

ODRATE® (WCK 6777)

FOVISCU® (WCK 4282)

EMROK® / EMROK O®

 Completion of Phase I clinical study in collaboration with NIH, USA

 Completion of Phase II clinical study

 Emrok treated >100k patients cumulatively; 

Launched in other divisions for additional indications

Insulin Aspart

 Filed for marketing approval to DCGI, India

Key positives for FY24-25

Sales Growth

Operational Excellence Cost reductions & Achievements

Emerging Markets

10%

Manufacturing Re-structuring - External to Internal

India Branded Business

Biotech New Business

Energy cost reduction initiative activated

~$30 Mn

Wastage reduced from last year

Capital raise of INR 1,000 Cr. through QIP

Financial Highlight: 67% EBITDA growth1

Total Income1 in INR Cr.

EBITDA1 in INR Cr.

5% growth1

67% growth1

2,879

3,033

251

FY24

FY25

EBITDA Margin

FY24

FY25 vs FY24, excluding exchange rate fluctuations

418

FY25

14%

Net Debt : Equity @ 0.011

Equity INR Cr.

Net Debt1 INR Cr.

Debt Reduction by INR 397 Cr.1

4,202

3,662

4,657

882

975

461

As at

31st Mar'22

31st Mar'23

31st Mar'24

31st Mar'25

As at

31st Mar'22

31st Mar'23

31st Mar'24

31st Mar'25

Cash & Cash Equivalents and other Bank Balances INR Cr.

Net Debt-Equity Ratio1

406

124

544

615

0.21

0.27

0.13

0.01

As at

31st Mar'22

31st Mar'23

31st Mar'24

31st Mar'25

As at

31st Mar'22

31st Mar'23

31st Mar'24

31st Mar'25

As at 31st March 2025, excluding promoter debt & net of cash & cash equivalents and other bank balances (Net Debt: INR 64 Cr.; Equity: INR 4,657 Cr.)

Short-term and Mid-term growth drivers

3 years growth drivers

5 years growth drivers

Diabetes Biosimilars for India + Emerging markets

Glargine, Insulin Analogues,

Human Insulin

New Insulin Analogues,

GLP-1 Analogues

Zaynich® (WCK 5222),

Miqnaf® (Nafithromycin),

Novel drug discovery

Emrok® & Emrok O®

Foviscu® (WCK 4282),

Odrate® (WCK 6777)

New Chemical Entity (Novel Antibiotics)

Wockhardt drug discovery efforts focused on the antibiotics segment

~145

~25 years

Drug Discovery team with more than 50 PhD’s.

Focused commitment to Novel Antibiotics research leading to end-to- end Discovery & Development capabilities

Programs granted QIDP* status by US FDA denoting unmet needs; abridged trials, faster review and approvals by US FDA

* Qualified Infectious Disease Product (QIDP) status granted by US FDA eligible for fast track development process and priority review. QIDP status also grants five year extension to the

market exclusivity in the United States

Novel Antibiotics pipeline encompassing all the Resistant Organisms

Gram Negative Portfolio

Gram Positive Portfolio

ZAYNICH® (WCK 5222)

FOVISCU® (WCK 4282)

ODRATE® (WCK 6777)

EMROK® / EMROK O®

MIQNAF® (Nafithromycin)

Status

Global Phase III Completed

Carbapenem resistant pathogen study (India) completed

Phase III ongoing

Phase I Completed In collaboration with NIH (US)

Launched in India; Filed in Emerging Markets

Launched in India

Potential Indication

cUTI, HABP / VABP (Global) + Carbapenem Resistant infections (India)

cUTI HABP / VABP

cUTI

ABSSSI

CABP / RTI

Target Market

Global

Emerging Market

Positioning

Destination therapy for difficult-to-treat Gram-ve Klebsiella, Acinetobacter and Pseudomonas

Empiric-use; Carbapenem- sparing Gram-ve

Out-patient therapy for MDR Gram -ve

MDR Gram+ve Anti-MRSA

Macrolide-resistant Respiratory Pathogens, Quinolone-Sparing

ZAYNICH® (WCK 5222)

Establishing ꞵ-lactam enhancer - a new class of antibiotic to treat MDR/XDR Gram-negative infections

ZAYNICH® (WCK 5222): New class of antibiotic after >30 years to treat Gram-negative infections Global Phase III clinical study completed

Global Phase III clinical study: achieved 20% higher (statistically superior) composite cure over gold standard Meropenem

Phase II Carbapenem-Resistance Organism study completed with >90% clinical efficacy

Saved 51 lives so far in compassionate usage including 3 in USA Patients had failed all available therapies: Penems, Ceftazidime+Avibactam, Cefiderocol, Colistin/Polymyxins; Safety established through extensive usage

Only product granted with investigational breakpoint of 64 mg/L for all major gram-negative pathogens by CLSI, USA

CLSI: Clinical and Laboratory Standards Institute

ZAYNICH® (WCK 5222) Regulatory status

India: Filed to DCGI* Approval / launch expected in H2 FY25-26.

US: Pre-NDA meeting completed with US FDA in May 2025 Filing to the US FDA in Q2 FY 25-26 with potential launch in FY26- 27

Europe & Emerging markets: Filing in H2 FY26

DCGI: Drug Controller General of India; Apex regulatory authority in India for granting approvals

Addressable pool of ~2 million patients in select markets for ZAYNICH® (WCK 5222)

Europe

~213Kc patients

USA

~158Kc patients

China

~657Ka patients

India

~1,109Kb patients

Excluding: Rest of World, Japan & Russia

a) b) c)

China : Adapted and derived using China incidence/epidemiology papers & CHINET China Bacterial Drug Resistance Surveillance Results (January-December 2022) India: Adapted and derived using India incidence studies and ICMR Anti Microbial Resistance Research & Surveillance Network 2022 US & Europe: Adapted and derived using epidemiology data and carbapenem resistance to key pathogens

~1.1 Million cases in India addressable by ZAYNICH® (WCK 5222) for key indications

Total cases*

~2.2 -3.1 Mn

Carbapenem resistance %

Carbapenem Resistance cases

~1.4 -2.0 Mn

Cases not treated by newer treatment options

Addressable cases for ZaynichTM

~1,109K

Acinetobacter B. ~0.5-0.7 Mn

Pseudomonas A.

~0.6-0.8 Mn

K. Pneumonia

~0.6-1.0 Mn

94%

51%

70%

E. Coli

~0.4-0.6 Mn

40%

~0.5-0.6 Mn

100%

~0.3-0.4 Mn

91%

~0.4-0.7 Mn

~0.2 Mn

10%

78%

~0.56 Mn

~0.34 Mn

~0.06 Mn

~0.16 Mn

• •

Excludes Complicated Urinary Tract Infection patients due to available treatment options – select patients would be available as addressable patient pool for WCK 5222, which would be an upside Patient population derived on basis of ICMR AMR Report 2022 & other epidemiology data sources.

ZAYNICH® (WCK 5222) addressable market in India

Total cases affected by Key Pathogens (E.coli, Klebsiella P., Pseudomonas A., Acinetobacter B)

~2.2 -3.1 Mn

Carbapenem Resistance cases for key pathogens

~1.4 -2.0 Mn

Carbapenem resistance cases not treated by newer therapy options and addressable by WCK 5222

~1.1 Mn

Addressable market potential (INR Cr.)

~INR 17K Crores

WCK 5222 addressable market opportunity of ~US$ 7 billion in USA and Europe

Addresses major Gram-negative infections cUTI, HABP/VABP, BSI, cIAI, indications

Pathogen coverage includes: Carbapenem resistant Acinetobacter B (CRAB), Carbapenem resistant Enterobacterales (CRE), Carbapenem resistant Pseudomonas A (CRPA) & Carbapenem resistant Stenotrophomonas including MBL producers

~371K carbapenem resistant cases in US & Europe ~4.3 million hospitalized cases for key gram-negative pathogens

New class antibiotic WCK 5222 offers addressable market opportunity of ~US$ 7 billion in USA & Europe

MIQNAF® (Nafithromycin) Next generation respiratory tract infection antibiotic

Wockhardt has ended a wait of > 30 years for a new antibiotic in Macrolide class with approval and launch of Miqnaf® (Nafithromycin)

MIQNAF® (Nafithromycin): Broad spectrum novel lactone ketolide for Community Acquired Bacterial Pneumonia (CABP) & Upper Respiratory tract infections(RTI)

Increasing resistance and incomplete coverage for current treatment options: − Macrolides (Azithromycin, Erythromycin) resistance in S. Pneumonia of ~65% in India − Lack of atypical pathogen coverage by Amoxicillin/Clavulanic acid

Nafithromycin has broad spectrum (covers entire range of gram +ve, gram -ve & atypicals) enabling monotherapy; effective against Azithromycin resistant strains / multi-drug resistance bacteria with 100% coverage based on high lung concentrations

Best-in-class Lung concentration (Human lung exposure 8 times higher than Azithromycin) allowing for Ultra short duration therapy (3 day) with once-a-day dosing

Successfully completed phase III study with 96.77 % of cure rate in CABP and other respiratory infections, with safety profile commensurate with community usage

India Marketing approval granted and launched QIDP status granted by USFDA indicating significant unmet need Breakthrough Medicinal Product (BMP) designation granted in Saudi Arabia; NDA filed

MIQNAF® (Nafithromycin) outperforms current CABP 1st line treatment options in terms of efficacy, treatment options and safety

Resistance (%) in S. Pneumoniae + H. Influenza

k r a M %

e Indian market size at generic prices (INR Cr.)* z s

t e

Days of Therapy (Mn) #

y Efficacy for macrolide-, t i v i t c a

penicillin- & quinolone-resistant S. pneumoniae

Efficacy for atypical RTI1 pathogens

a i r e t c a b - i t n A

t n e m t a e r T

s n o i t p o

/ y t e f a S

e s r e v d a

s t n e v e

Coverage of MDR H. influenzae

Prevalence of resistance

3-day therapy potential

Lung concentration for resistant strains

Pediatric use potential

Hepatic safety

Drug-drug interaction potential

C. difficile diarrhoea potential

Macrolide

Penicillin

Cephalosporin

MIQNAF® (Nafithromycin)

Azithromycin

Clarithromycin

Amoxicillin + Clavulanic acid

Cefixime / Cefpodoxime

Yes

MOA driven low propensity

Yes

High

Yes

Up to 65%

1,078

526

Yes

High

Yes

Low

Yes

145

Yes

High

Low

Yes

Moderate

11%

2,272

260

High

Low

Yes

Up to 42%

1,736

419

High

Low

Yes

P Patent protection

Assured

Expired

*Source: IQVIA

# Derived from IQVIA

MIQNAF® (Nafithromycin): Addressable market in India

RTI is one of the leading Rx category in India with ~367 Mn Rx

• •

62 Million Lower Respiratory Tract Infection Rx 305 Million Upper Respiratory Tract Infection Rx

Antibiotics market size for Respiratory Tract Infection (RTI) in India (at current generic prices) is ~INR 6,500 Cr.

Miqnaf® is targetting 96 Mn* Rx segment of relevant doctor specialities, with addressable market opportunity of ~INR 10,800 Cr.

* does not include potential upside of Rx by GP

Biotechnology

Competitive advantage in Diabetes Biosimilars: Integrated capabilities from lab to patient

R&D Capabilities:

• Yeast, Bacterial & Mammalian expression • Focused only on Diabetes segment - Insulin, Insulin Analogues • Product development, process development, analytical development &

analytical bio similarity

Drug Substance (DS) manufacturing • DS facility with 4 blocks for different expression systems using E. coli, mammalian and yeast

Commercialization model

India

• Through own field force for promotion to Diabetologists/ Endocrinologists

Emerging Market

• Through partners / distributors in >30

countries

Integrated capabilities

Drug Product (DP) manufacturing • Flexibility of drug product manufacturing at India

facility (2 sites)

Devices • Patented delivery devices (Disposable & Re-usable)

Patented delivery devices (pen)

Vials

Cartridges

Diabetes Biosimilars for Emerging markets - Competitive scenario

Limited competition

6-7

players

Registered in emerging markets

Competitive scenario

Manufacturing infrastructure ready

Integrated end to end capabilities

Focus on Human Insulin & Glargine

>30

markets

Drug substance + Products

Development to marketing

> US$ 1.5 Billion market

Pipeline: Aspart R (filed in India) & Aspart Mix

~ US$ 700 Million market

Significant opportunity opening up in Human Insulin due to changing market dynamics

Novo Nordisk intends to discontinue its Human disposable insulin pens and cartridges.

Change in market dynamics

Initiative to increase production of GLP-1 analogues

~INR 450 Cr.

• Novo Nordisk's phase-out of Human Insulin cartridges and dispopen provides an

opportunity worth ~INR 450 Cr. In India

• Only 3 key players including Wockhardt to benefit from this opportunity

Emerging Markets*

~US$ 157 Mn

• Novo Nordisk's phase-out of Human Insulin cartridges and dispopen provides an

opportunity worth ~US $157 Mn in Emerging markets

Wockhardt's strong position in Insulin will enable to capitalize this opportunity

*Emerging markets: excluding China & India

Comprehensive antidiabetic biosimilars pipeline across Human Insulin & Insulin analogs targeting India and Emerging Markets

Recombinant Human Insulin

Glargine 100 IU

Commercialized Products

Product Pipeline

Aspart R

Aspart 30/70

Lispro R

Process development

Process Scale Up

Drug substance validation batches

Drug product validation batches

PK/PD study

Analytical similarity

✓

✓ Completed * To be further scaled up

✓

Planned

✓

✓*

Planned

Strategic growth levers

Robust Business performance driven by operational leverage

Novel Antibiotic Portfolio : Best-in-class portfolio across infection spectrum targeting high value global markets

Zaynich: A Breakthrough innovation − Life-saving innovation for gram negative infections − TAM of ~US$ 9 bn in US, Europe and India

Miqnaf: Oral Antibiotic for RTI − New antibiotic in Macrolide class after > 30 years − TAM of ~INR 10,800 Cr. in India

Diabetes Biosimilars − Uniquely positioned diabetes portfolio (EM market size of US$ 3 bn) with end-to-end capabilities − Doubling capacity in next 3 years to tap growing demand that would help business to grow at 20-25%

TAM: Total Addressable Market

Abbreviations

®: Registered ~: Approximate A.baumannii: Acinetobacter baumannii ABSSSI: Acute bacterial skin and skin structure infections AmpC: Ampicillin-resistance gene group C AMR: Anti Microbial Resistance ꞵ-lactam: Beta Lactam Bn: Billion BSI: Blood Stream infection CABP: Community-acquired bacterial pneumonia CAZ/AVI: Ceftazidime-avibactam CDSCO: Central Drugs Standard Control Organization cIAI: Complicated Intra-abdominal Infections CLSI: Clinical & Laboratory Standards Institute, USA Cr.: Crore CRAB: Carbapenem-Resistant Acinetobacter baumannii cUTI : Complicated urinary tract infections EBITDA : Earnings before interest, taxes, depreciation, and amortization

E.coli: Escherichia coli EU: European Opinion Gram –ve: Gram negative Gram +ve: Gram positive HABP: Hospital Acquired Bacterial Pneumonia ICMR: Indian Council of Medical Research ICU: Intensive care unit IND: Investigational New Drug INR: Indian rupee IU – International Unit IV: Intravenous K Pneumoniae :Klebsiella pneumoniae KPC: Klebsiella pneumoniae carbapenemase MBL: Metallo-beta-lactamase MDR: Multidrug resistance MDR/XDR: Multi Drug Resistant/ Extremely drug resistant Mn – Million MOA: Mechanism of Action MOH – Ministry of Health MRSA: Methicillin-resistant Staphylococcus aureus

NCE: New chemical entity NDA: New Drug Application NIH: National Institute of Health PhD: Doctor of Philosophy PK: Pharmacokinetics PK/PD – Pharmacokinetics/Pharmacodynamics QIDP: Qualified Infectious Disease Product R&D: Research and Development RTI: Respiratory Tract Infection S. maltophilia : Stenotrophomonas maltophilia TID: Thrice a day UK: United Kingdom US: United States US-FDA: United Stated Food and Drug Administration VABP: Ventilator Acquired Bacterial Pneumonia WHO: World Health Organization Y-o-Y: Year-over-year

Thank you

← All Transcripts WOCKPHARMA Stock Page →

Wockhardt Limited has informed the Exchange about Investor Presentation

Market Movers